Bayer's Experimental PET Tracer Demonstrates High Accuracy in Detecting Cardiac Amyloidosis
Bayer announced that its experimental positron emission tomography (PET) tracer demonstrated high accuracy in identifying cardiac amyloidosis during a Phase 3 clinical trial. The imaging agent achieved a sensitivity of 94% and specificity of 86%, based on evaluations by independent scan readers. The results come from the REVEAL trial, which tested iodine-124 as an innovative diagnostic tool for detecting cardiac amyloidosis—a condition where abnormal proteins accumulate in heart tissue. The high accuracy rates suggest potential clinical utility if approved and adopted widely. This development could position Bayer's tracer as a valuable addition to current diagnostic methods, potentially improving early detection of the disease and influencing treatment decisions.
Topics: Bayer cardiac amyloidosis imaging agent